Forxiga: Novel Type 2 Diabetes Drug Wins EMEA Approval-Potential to Benefit T1D Posted on April 1, 2012 by JDRF
Role of Glucagon in the Pathophysiology of Diabetes: Hypothesis Around a Primary Causal Relationship Posted on January 1, 2012 by JDRF
Incretins, A Class Of Drugs Currently Approved For The Treatment Of Type 2 Diabetes, Can Benefit Individuals With Type 1 Diabetes By Improving Glucose Control And Reducing The Total Daily Dose Of Insulin Posted on July 1, 2011 by JDRF